Lymphoproliferative disorders after liver transplantation

Leblond, Véronique; Choquet, Sylvain

doi:10.1016/j.jhep.2004.03.006

Cited by 58 publications

(58 citation statements)

References 45 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Previous reports of PTLD following OLT in adults have reported frequencies in the 2% to 3.5% range (10). Using competing risk survival analysis, we observed a cumulative incidence of 5.4% at 15 1 / 2 years post-transplant.…”

Section: Discussionmentioning

confidence: 48%

Post-Transplant Lymphoproliferative Disorders Following Liver Transplantation: Incidence, Risk Factors and Survival

Kremers¹,

Devarbhavi²,

Wiesner³

et al. 2006

American Journal of Transplantation

133

View full text Add to dashboard Cite

This study investigates retrospectively the incidence, risk factors and mortality of post-transplant lymphoproliferative disorders (PTLD) in adult orthotopic liver transplant (OLT) recipients. Among 1206 OLT recipients at a single institution, 37 developed a PTLD. The incidence of PTLD was highest during the first 18 months and relatively constant thereafter with cumulative incidence of 1.1% at 18 months and 4.7% at 15 years. The risk of PTLD was approximately 10% to 15% of the risk of death without PTLD. During the first 4 years following OLT, PTLD were predominantly related to EBV, while afterward most PTLD were EBV negative. Significant risk factors for PTLD in OLT recipients were transplantation for acute fulminant hepatitis during the first 18 months following OLT (HR = 2.6, p = 0.007), and rejection therapy with high-dose steroids (HR = 4.5, p = 0.049) and OKT3 (HR = 3.9, p = 0.016) during the previous year. Therapy with high-dose steroids or OKT3 (HR = 3.6, p = 0.0071) were also significant risk factors for PTLD-associated mortality. OLT recipients remain at risk for PTLD years after transplantation. The strong association of PTLD with rejection therapy and the worse post-PTLD prognosis among recipients of rejection therapy indicate the need to balance the risk of immunosuppression against the risk of PTLD following rejection treatment.

show abstract

Section: Discussionmentioning

confidence: 48%

Post-Transplant Lymphoproliferative Disorders Following Liver Transplantation: Incidence, Risk Factors and Survival

Kremers¹,

Devarbhavi²,

Wiesner³

et al. 2006

American Journal of Transplantation

133

View full text Add to dashboard Cite

show abstract

“…PTLD is a lymphoma observed after transplantation, and occurs particularly frequently among young children after kidney or heart transplantation [11]. Although various etiological factors have been considered, the use of antilymphocyte antibodies and EBV infection are commonly cited.…”

Section: Discussionmentioning

confidence: 99%

Epstein-Barr Virus-Negative Lymphoproliferative Disorders after Liver Transplantation

Shimoda¹,

Kita²,

Kato³

et al. 2008

TOTRANSJ

View full text Add to dashboard Cite

Lymphoproliferative disorders following liver transplantation are often Epstein-Barr virus (EBV)-related highgrade B cell lymphomas. EBV-negative and low-grade lymphoma is a very rare condition after cadaveric as well as living donor liver transplantation (LDLT). Herein we report a case of follicular lymphoma with negative EBV viral capsid antigen (VCA), IgM, IgG and Epstein-Barr virus-encoded small RNA (EBER), which developed after LDLT, and review the literature pertaining to EBV-negative post-transplantation lymphoproliferative disorder (PTLD) after liver transplantation.

show abstract

“…However the true incidence of PTLD in adult and paediatric recipients is difficult to determine with accuracy (Leblond V & Choquet S, 2004;Patel H et al, 2007).…”

Section: Epidemiologymentioning

confidence: 99%

“…Recent data also suggest Hepatitis B virus reactivation as a possible risk factor for development of PTLD ( Leblond V & Choquet S, 2004;Duvoux C et al, 2002;Zhang A et al 2009).…”

Section: Introductionmentioning

confidence: 99%